October 21, 2014 3:27 AM ET

Biotechnology

Company Overview of Chimerix, Inc.

Company Overview

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel, oral antivirals to address unmet medical needs in the United States. Its lead compounds include brincidofovir (CMX001), which is in Phase III clinical development; CMX157, a nucleotide analog that has completed Phase I study for the treatment of HIV infections. The company’s proprietary lipid technology and chemical library is under discovery and preclinical stage of development. It has collaboration and license agreement with Merck Sharp & Dohme Corp. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.

2505 Meridian Parkway

Suite 340

Durham, NC 27713

United States

Founded in 2000

59 Employees

Phone:

919-806-1074

Fax:

919-806-1146

Key Executives for Chimerix, Inc.

Chief Executive Officer
Age: 47
Total Annual Compensation: $340.0K
Chief Financial Officer
Age: 56
Total Annual Compensation: $275.0K
Chief Development Officer
Age: 60
Total Annual Compensation: $228.1K
Compensation as of Fiscal Year 2013.

Chimerix, Inc. Key Developments

Chimerix, Inc. Announces New Product Candidate, CMX16669 to Development Pipeline

Chimerix, Inc. provided an update on the company's R&D programs, including the addition of a potential new product candidate, CMX16669, to its development pipeline. The company has discovered, developed and selected a novel clinical candidate, CMX16669, for BK virus and cytomegalovirus (CMV). This new product candidate has demonstrated potent in vitro activity against CMV and BK virus, with a promising safety profile in vitro and in pilot toxicity studies in animals. The modified lipid tail may enable very low oral doses, based on initial animal studies. The company plans to initiate clinical trials in 2015.

Chimerix, Inc. - Special Call

To discuss the company's R&D update and annual Meeting

Chimerix, Inc. Announces Preliminary Data for its Investigational Antiviral Brincidofovir

Chimerix, Inc. announced preliminary data for its investigational antiviral brincidofovir (BCV, CMX001) showing improved survival for patients with adenovirus in the open-label pilot portion of the Phase 3 AdVise Trial. The preliminary survival analysis data, based on 48 evaluable patients from the ongoing AdVise Trial, showed a mortality rate of 35% compared with the historic rates of up to 80% mortality in the first month after diagnosis. A majority of subjects also had suppression or clearance of adenovirus from the blood. There is currently no approved treatment for adenovirus, an infection that can progress rapidly in patients with a weakened immune system due to disease or medications. Chimerix initiated AdVise in March 2014 based on potency observed in vitro and on clinical data from a Phase 2 trial and a large expanded access trial which showed the potential for improved clinical outcomes. The trial is enrolling pediatric and adult patients with adenovirus infection who receive brincidofovir twice weekly for twelve weeks. Baseline information and at least two months of follow up are available for 26 subjects. Of those 26 patients, 23 had measurable viral loads at study entry, and three patients had no virus detectable in the blood but had diagnosed adenovirus infection. Fourteen of the 23 patients with viremia at study entry achieved undetectable viral loads during treatment. Twelve of the 26 patients died. Over half of the subjects were hematopoeitic cell transplant (HCT) recipients with disseminated disease, but solid organ transplant recipients and patients undergoing chemotherapy were also enrolled. Over one-third of the subjects (10 of 26) had a second active infection with another DNA virus in addition to adenovirus, including BK virus (27%), cytomegalovirus (19%) and Epstein Barr virus (8%). The safety and tolerability profile of brincidofovir in these initial subjects was similar to other studies of brincidofovir in immunocompromised patients with complicated medical issues, with only three subjects discontinuing due to adverse events. Of the six subjects who enrolled in the study with adenovirus-related diarrhea, three reported improvement of symptoms and three remained stable.

Similar Private Companies By Industry

Company Name Region
CytRx Oncology Corporation United States
EndoVention Inc. United States
Tolerance Therapeutics LLC United States
Crescendo Pharmaceuticals Corporation United States
Empire Genomics, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Chimerix, Inc., please visit www.chimerix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.